ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
September 13, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Phoenix Based BioNovelus Announces a New Product for the Health Disinfectant Industry
June 22, 2017 07:00 ET
|
BioNovelus Inc.
Phoenix, June 22, 2017 (GLOBE NEWSWIRE) -- / At the recent ExpoMed Show in Mexico City, BioNovelus (ONOV) Chairman and founder, Jean Ekobo, was proud to introduce the newest addition to the...
ContraFect Chairman Steven C. Gilman Returns from Temporary Medical Leave
May 30, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics...
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
May 25, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces First Quarter 2017 Financial Results
May 08, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 08, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI
May 02, 2017 09:38 ET
|
Melinta Therapeutics
New Haven, Conn, May 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced an upcoming...
ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
April 19, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - April 19, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
March 13, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 13, 2017) - ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
March 02, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Lisa Ricciardi to Join Board of Directors
February 15, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - February 15, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...